These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22748874)

  • 1. Editorial comment.
    Nelson PS
    Urology; 2012 Jul; 80(1):180-1; author reply 181. PubMed ID: 22748874
    [No Abstract]   [Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
    Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
    Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
    Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
    Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinizing hormone-releasing hormone antagonists in prostate cancer.
    Stricker HJ
    Urology; 2001 Aug; 58(2 Suppl 1):24-7. PubMed ID: 11502441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomized Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists.
    Irani J
    Eur Urol; 2015 Aug; 68(2):339. PubMed ID: 26149730
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
    Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
    Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
    J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
    Moul JW
    BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
    [No Abstract]   [Full Text] [Related]  

  • 12. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
    Boccon-Gibod L; Iversen P; Persson BE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
    Pickles T
    J Urol; 2005 Dec; 174(6):2423-4; author reply 2424. PubMed ID: 16280866
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
    Yannucci J; Manola J; Garnick MB; Bhat G; Bubley GJ
    J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. IJROBP 2002;52: 439-443.
    Dearnaley DP; Norman AR; Shahidi M
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):981; author reply 981. PubMed ID: 12377353
    [No Abstract]   [Full Text] [Related]  

  • 16. Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide.
    Iversen P; Karup C; van der Meulen E; Tankó LB; Huhtaniemi I
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):184-90. PubMed ID: 21445092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?
    van Poppel H; Nilsson S
    Urology; 2008 Jun; 71(6):1001-6. PubMed ID: 18407326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gn-RH antagonist possible response, after Gn-RH agonist failure in a man with metastatic prostate cancer.
    Rocco B; Ferrari M; Scardino E; Matei DV; Verweij F; Varela R; De Cobelli O
    Anticancer Res; 2005; 25(1B):577-8. PubMed ID: 15816630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
    Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
    Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.